NASDAQ:PSTV Plus Therapeutics Q2 2026 Earnings Report $3.91 -0.05 (-1.26%) As of 08/5/2026 ProfileEarnings HistoryForecast Plus Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.88Beat/MissN/AOne Year Ago EPSN/APlus Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.11 millionBeat/MissN/AYoY Revenue GrowthN/APlus Therapeutics Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateFriday, August 14, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Plus Therapeutics Earnings HeadlinesPlus Therapeutics (PSTV) Projected to Announce Earnings on ThursdayAugust 6 at 2:56 AM | americanbankingnews.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Recommendation of "Hold" from BrokeragesAugust 3, 2026 | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology CompanyJuly 31, 2026 | finanznachrichten.deCerenome Launches as an Integrated CNS Oncology CompanyJuly 31, 2026 | globenewswire.comPlus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases ConferenceJuly 28, 2026 | globenewswire.comSee More Plus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email. Email Address About Plus TherapeuticsPlus Therapeutics (NASDAQ:PSTV) is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases. The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors. Plus Therapeutics has secured orphan drug and rare pediatric disease designations for select compounds, reflecting its focus on addressing unmet needs in both adult and pediatric oncology. Clinical studies are conducted in collaboration with academic medical centers and contract research organizations across North America. Headquartered in Austin, Texas, Plus Therapeutics is led by an executive team with extensive experience in radiopharmaceuticals and oncology drug development. The company maintains research, manufacturing and administrative operations in the United States and continues to expand strategic partnerships to advance its targeted radiotherapeutic portfolio.View Plus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boeing's Comeback Is Building Momentum—Is It Real?Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is FallingBed Bath & Beyond Renovates: The Neighborhood BlueprintSpaceX: Love the Company, But the Stock Is a Harder CallDisney Sets Up for a Magical Year in 2027Astera Labs' Post-Earnings Pullback May Be Last Chance to Buy Below $360Why Analysts Are Bullish on a Stock That's Down 20% Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)Nebius Group (8/12/2026)NetEase (8/13/2026)Brookfield (8/13/2026)NU (8/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
